International Journal of Pharmaceutical Biological and Chemical Sciences

Research Article

Improve oral bioavailability of aceclofenac using solid dispersions by dropping method

Venkatewara Reddy.B*[1], M.Vijaya Gopal[1], Jyosna.D[1], K.V.Ramana Murthy[2]

[1]Department of Pharmaceutics, St.Paul's college of Pharmacy, Ranga Reddy, A.P, INDIA
[2]college of Pharmaceutical sciences, Andhra University, Visakhapatnam, A.P, INDIA
Corresponding author Email: basu.pharmacist@gmail.com

ABSTRACT

The objective of the present investigation was to study the effect of polyethylene glycol 8000 (PEG 8000) on *in vitro* dissolution of Aceclofenac from solid dispersions. Initial studies were carried out using physical mixtures of the drug and carrier. Solid dispersions were prepared by the dropping method. Aceclofenac was formulated as physical mixtures and solid dispersions (dropping method) using 1:2, 1:4, 1:6 and 1:8 ratios of drug and carrier (PEG 8000). Saturation solubility study for pure drug, physical mixtures and solid dispersions were carried out in water and pH 6.8 phosphate buffer solutions (PBS). The *In vitro* dissolution studies were carried in pH 6.8, higher *in vitro* dissolution of solid dispersions was recorded compared to their corresponding physical mixtures and the pure drug. The prepared solid dispersions showed marked increase in the saturation solubility and dissolution rate of Aceclofenac than that of pure drug. PEG 8000 in 1: 8 drug to carrier ratio exhibited the highest drug release (98.83%) formulated as solid dispersions using dropping method. The FT-IR shows the complexation and there were no interactions. Finally solid dispersion of Aceclofenac: PEG 8000 prepared as 1:8 ratio by dropping method showed excellent physicochemical characteristics and was found to be described by dissolution release kinetics and was selected as the best formulation.

KEYWORDS

Solid dispersions, Aceclofenac, dropping method and PEG-8000.

INTRODUCTION

Oral bioavailability of drugs depends on its solubility and/or dissolution rate, therefore major problems associated with these drugs was its very low solubility in biological fluids, which results into poor bioavailability after oral administration. Many methods are available to improve dissolution rate, solubility characteristics, including salt formation, micronization or nanonization, and addition of solvent or surfaceactive agents. SDs is one of these methods, which was most widely and successfully applied to improve the solubility, dissolution rates and consequently the bioavailability of poorly soluble drugs[1].

In contrast, amorphous systems with excess thermodynamic properties and lower energetic barrier can offer significant solubility benefits[2]. This solubility benefit can be further enhanced by preparing solid dispersions (SDs). SDs contributes by slowing devitrification, enhancing wettability and modulating the properties of the solvent[3]. Solid dispersion is one of the effective and widely used techniques for dissolution enhancement[4]. The two basic procedures used to prepare solid dispersions are the melting or fusion[5] and solvent evaporation[6] techniques.

Aceclofenac is a new generation NSAID used in the treatment of osteoarthritis, rheumatoid arthritis and other joint diseases. It is chemically designated as 2-[[2-[2-[(2, 6-dichlorophenyl) amino] phenyl] acetyl] oxy] acetic acid which possesses remarkable anti-inflammatory, analgesic and antipyretic properties[7]. The analgesic efficacy of aceclofenac 100mg is more prolonged than that of acetaminophen 650mg. aceclofenac appears to be particularly well tolerated among the NSAID, with a lower incidence of gastrointestinal adverse effects.

Aceclofenac exhibits very slightly solubility in water and as consequence it exhibits low bioavailability of aceclofenac dissolution from its oral solid dosage forms is an important issue for enhancing its bioavailability and therapeutic efficacy[8].

Polyethylene glycol (PEG) is used for the preparation of solid dispersions. A particular advantage of PEGs for the formation of solid dispersions is that they have good solubility in many organic solvents. The melting point of PEGs lies below 65 ^{0}C in all cases[9], which is advantageous for the manufacture of solid dispersions. Aceclofenac was chosen as a model candidate because of its low dissolution rate and solubility-limited bioavailability.

MATERIALS AND METHODS

Materials

Aceclofenac was a gift sample from M/S Seeko Biotech, Vijayawada, A.P, poly ethylene glycol 8000 was purchased from Merk, Mumbai, Potassium dihydrogen orthophosphate (Qualigens fine chemicals, Mumbai), Sodium hydroxide (Finar chemicals ltd. Ahemdabad)

and methanol (Research-Lab fine chemicals industries, Mumbai). All required chemicals were analytical grade.

METHODS

Preparation of Physical Mixture:

Physical mixtures of Aceclofenac at four different mass ratios (1:2, 1:4, 1:6 and 1:8) with PEG 8000 was prepared in a glass mortar by light trituration for 5 minutes. The mixtures were passed through a sieve no: 60. The prepared mixtures were then filled in hard gelatin capsules, sealed and stored in a dessicator until further use. The composition of PM1, PM 2, PM 3 and PM 4 formulations were shown in **table no: 1.**

Table: 1 Composition of Aceclofenac Physical Mixtures and Solid Dispersions

Ingredients (mg)	PM1	PM2	PM3	PM4	SD1	SD2	SD3	SD4
Aceclofenac	100	100	100	100	100	100	100	100
PEG-8000	200	400	600	800	200	400	600	800

Preparation of Solid Dispersion by Dropping Method:

For the preparation of the Aceclofenac solid dispersions prepared by dropping method, containing different weight ratios of Aceclofenac in PEG 8000. The composition of SD1, SD2, SD3 and SD4 formulations was shown in **table no: 1**. The PEG was melted in a porcelain dish at 58 ^{0}C (±1^{0}C) and a measured amount of Aceclofenac were added and stirred. The melted drug–carrier mixture was pipetted and placed into an adjustable heating device to keep the temperature constant. The melted drug–carrier mixture was dropped onto a stainless steel plate, where it solidified into round particles. The temperature of the stainless steel plate was <20 ^{0}C. The round particles (equivalent to 100 mg of Aceclofenac) were placed into hard gelatin capsules (size no. 2) for further investigations.

PHYSICOCHEMICAL CHARACTERIZATION

Phase solubility studies:

Phase and saturation solubility studies were performed according to the method described by Higuchi and Connors[10].The saturation solubility of drug and SDs with PEG 8000 (1:2, 1:4, 1:6 and 1:8 w/w) in distilled water and phosphate buffer (pH 6.8) were determined by adding an excess of drug and SDs to 50 ml distilled water or Phosphate buffer in conical flask and were rotated in a orbital shaking incubator for 96 hrs at 37 ^{0}C ±0.5 ^{0}C. The saturated solutions were filtered through a 0.45 µm membrane filter, suitably diluted with water, phosphate buffer and analyzed by UV spectrophotometer at 275nm, Lab India Double Beam UV-3000+, India.

FT-IR Spectroscopy:

Fourier transmitted Infrared (FT-IR) spectroscopy was conducted using Thermo Nicolet Nexus 670 Spectrophotometer and the spectrum was recorded in the wavelength region of 4000 to 500 cm^{-1}. The procedure consisted of dispersing a sample (drug alone or mixture of drug and excipients) in KBr and compressing into discs by applying a pressure. The pellet was placed in the light path and the spectrum was obtained.

Drug content estimation[11]:

The drug content in each solid dispersions and physical mixture was determined by the UV-Spectroscopic method. An accurately weighed quantity of solid dispersion or physical mixture, equivalent to 100 mg of Aceclofenac, was transferred to a 100 mL volumetric flask containing 10 mL of methanol and dissolved. The volume was made up to 100 mL with pH 6.8. The solution was filtered and the absorbance was measured after suitable dilutions by using Lab India Double Beam UV-Spectrophotometer at 275nm.

***In vitro* drug dissolution studies:**

Dissolution rate studies were performed in pH 6.8 phosphate buffer at 37 ± 0.5 ^{0}C, using USP type-II apparatus with paddle rotating at 75 rpm. Solid products, solid dispersions as well as physical mixtures, each containing 100 mg of drug were subjected to dissolution. At fixed time intervals, samples withdrawn were filtered and spectrophotometrically analyzed at 275 nm. Each test was performed in triplicate (n=3). Dissolution efficiency (DE) was calculated from the area under the dissolution curve at time t (measured using the trapezoidal rule) [12]. The similarity factor (f2) was evaluated to compare Aceclofenac release profiles.

$$f2 = 50 \log \{[1+1/n \sum_{t=1}^{n} (Rt - Tt)^2]^{-0.5} \times 100\}$$

Where Rt and Tt were the cumulative percentage of drug released for reference and test assay at time 't' respectively, 'n' was the number of time points. The FDA suggests that two dissolution profiles are declared to be similar if the value of *f2* is between 50 and 100[13].

RESULTS AND DISCUSSION

The drug content in physical mixtures, solid dispersions with PEG 8000 as reported in **table: 2** were found to be in the range of 98.5% to 101.8%. Therefore, dropping method used in this study appears applicable for the preparation of solid dispersions without affecting drug content.

Table: 2 Solubility studies and drug content for pure drug, physical mixtures and solid dispersions

Formulation code	Solubility (µg/mL)		Drug content (%)
	Water	PBS	
Pure drug	27.04 ± 0.56	55.47 ± 1.15	98.56±0.023
PM -1	35.59 ± 1.12	61.73 ± 1.21	98.75±0.012
PM -2	46.87 ± 1.24	66.57 ± 1.25	99.87±0.025
PM -3	52.79 ± 1.35	74.59 ± 1.31	98.89±0.022
PM -4	55.59 ± 1.12	88.43 ± 0.78	99.74±0.031
SD-1	36.22 ± 1.05	63.26 ± 1.11	100.44±0.021
SD-2	48.86 ± 1.87	74.47 ± 1.03	100.05±0.013
SD-3	56.92 ± 1.46	82.52 ± 1.06	99.87±0.026
SD-4	58.52 ± 1.15	98.65 ± 1.24	101.82±0.041

When the physical mixture is added to the dissolution medium, it may simply happen that the carrier, which dissolves first, modifies the hydrophilicity/lipophilicity or wettability of the drug or it may form a weak complex with the drug at the particle surface, resulting in drug dissolution. An increase in the saturation solubility of the drug can explain the improved dissolution of solid dispersions as per the Noyes and Whitney equation[14], since the saturation solubility of a compound is dependent on the size of the particles. Since it is possible to achieve reduction in particle size with a solid dispersion system, the saturation solubility studies were performed with these systems. The results on saturation solubility indicated that the solubility was enhanced by 43 % compared to Aceclofenac.

Solubility Studies:

As the solid dispersion is a metastable form and tends to transform in to the stable form, the drug concentration may tend to decrease with elapse of time during the solubility test. In order to avoid this problem all the solubility test samples of the different formulations were withdrawn and analyzed at established time (96hrs). This allowed readily comparing the solubility of different solid dispersions. The solubility of different concentrations of drug and carrier was observed and the prepared formulation with PEG 8000 1:8 presented higher dissolution concentration as compared with the other formulations obtained with different ratios (1:2, 1:4 and 1:6). Maximum solubility in Phosphate buffer solution was observed in dropping method 1:8 (Drug: PEG 8000) ratio 98.65 ± 1.24 µg/mL, when compared with that of pure Aceclofenac (55.47 ± 1.15 µg/mL).

***In Vitro* drug release:**

The dissolution profiles of Aceclofenac for solid dispersion and physical mixture performed in 6.8 phosphate buffer were studied. The comparative cumulative release of Aceclofenac at various time intervals from the physical mixtures and solid dispersions made by using various concentrations of PEG 8000 are shown in **Figure: 1&2.** Dissolution of the pure drug, Aceclofenac, in PBS (pH 6.8) was only 51.06 %. Prepared physical mixtures and solid dispersions showed improvement in dissolution characteristics. In the first 30 minutes, physical mixtures of PEG 8000 (1:2, 1:4, 1:6 and 1:8) showed 30.47, 37.56,40.98 and 49.14 % drug released 48.67, 52.56, 56.75 and 64.97 %drug released from solid dispersions (1:2, 1:4, 1:6 and 1:8). After 60 min, physical mixtures with PEG 8000 showed 55.78, 63.56, 71.23 and 80.45 %drug released, whereas solid dispersions with PEG 8000 showed 80.56, 86.54, 91.36 and 98.83 % drug release, respectively.



Figure: 1 Comparison of Dissolution Profiles Using PEG-8000 by Physical Mixtures with Pure Drug



Figure: 2 Comparison of Dissolution Profiles Using PEG-8000 by solid dispersions with Pure Drug

Dissolution of the pure drug was found to be 47.12 % in 60 minutes. Almost half of the drug was dissolved from physical mixtures and solid dispersions in the first 30 minutes. After 60 min, physical mixture with PEG 8000 (1:8) showed 80.45 % release whereas maximum release was obtained solid dispersion with PEG 8000 (1:8) and was 98.83%.

Possible mechanisms of increased dissolution rates of solid dispersions have been proposed by Ford[15]. A reduction of crystallite size, solubilization effect of the carrier, absence of aggregation of drug crystallites, improved wettability and dispersibility of the drug from the dispersion, dissolution of the drug in the hydrophilic carrier, drug conversion to amorphous state and finally, a combination of the mentioned mechanisms. The increased dissolution rate in these cases can thus be attributed to several factors, such as the solubilization effect of the carrier, conversion to amorphous state, and improved wettability of Aceclofenac. In general, dissolution may be described by two processes: the rate of the interfacial or solid solvent reaction leading to solubilization of the molecule, and the rate associated with the diffusional or transport process of the solvated molecule to the bulk part of the dissolution medium. The strength of bonds between water and PEG and water and drug molecules may be stronger than or comparable with that between the molecules of the solid dispersions[16]. Upon contact, water molecules solvate the carriers and

Aceclofenac molecules, either in the crystalline or in amorphous form, and break the hydrogen bonds in the drug-carrier complexes.

The drug release from all the formulations followed first order kinetics, as the plot observed in between log% of un drug released Vs time was found to be linear. The corresponding release rate constant values were shown in **table: 3**.

Table: 3 Dissolution Kinetics of ACECLOFENAC Physical Mixtures and Solid Dispersions Formulated With PEG-8000

Formulation code	Correlation Coefficient (R^2)					Slope(n)	$DE_{30\%}$	$DE_{60\%}$
	Zero order	First order	Higuchi	Peppas	Hixson Crowell			
PM 1	0.9422	0.9191	0.9172	0.9072	0.9342	0.452	19.51	25.79
PM 2	0.9546	0.9356	0.9292	0.9134	0.9512	0.507	22.83	31.48
PM 3	0.9382	0.9102	0.8982	0.8915	0.9055	0.519	24.22	32.77
PM4	0.9381	0.9482	0.9147	0.9152	0.9482	0.482	21.60	30.95
SD1	0.9455	0.9623	0.8972	0.8649	0.9037	0.543	20.51	29.09
SD2	0.9562	0.9726	0.9135	0.8891	0.9286	0.522	23.48	34.58
SD3	0.9526	0.9785	0.9145	0.8883	0.9581	0.511	25.36	37.05
SD4	0.9322	0.9887	0.8723	0.8983	0.9742	0.525	26.91	39.78

***DE_{30} and DE_{60}, dissolution efficiency at 30 and 60 minutes.**

To analyze the mechanism of drug release from these formulations, the data were followed Hixson Crowell equation ({fraction unreleased} $^{1/3}$ vs. time). The release rate kinetic data & dissolution efficiency at 30 & 60 minutes ($DE_{30\%}$ & $DE_{60\%}$) for these formulations were given in **table: 3**. The slope values (n) obtained to decline Between 0.452 to 0.543 for all formulations for the release of Aceclofenac, indicating non-fickian diffusion. The dissolutions profile showed in (**figure: 3**) and similarity factor (f_2), these two formulations were found to be 86.72% indicating the significant differences in between the selected (SD4) and marketed tablet (**Lessen**).The above results indicated that the increasing concentration of PEG-8000 content enhanced the drug release. The release kinetics of Aceclofenac prepared from different methods of solid dispersions was observed and tabulated.

Spectroscopy studies:

The IR spectra of pure Aceclofenac and solid dispersions are shown in **Figures 4 and 5**.

The IR spectra of pure Aceclofenac showed characteristic peaks at C-H-(bending) 1342.62cm^{-1}, 1442.38cm^{-1}, 1502.45cm^{-1}.

C-O-(stretching) 1050.73 cm^{-1}, 1138.53 cm^{-1}.

C=O-(stretching) 1711.50cm^{-1}.

C-N (Amine) 1286.68cm^{-1}.

N-H-(stretching) 3314.48cm^{-1}.

It might be the possibility of intermolecular hydrogen bonding between adjunct Aceclofenac molecules. The spectrum of pure Aceclofenac was equivalent to the spectra obtained by the addition of carrier. This indicated that no interaction occurred with a solid dispersion of drug and lipid carriers. The results revealed no considerable changes in the IR peaks of Aceclofenac, when mixed with carrier PEG-8000. These observations indicated the compatibility of PEG-8000 with Aceclofenac.



Figure: 3 *In-vitro* Dissolution Profiles of Aceclofenac Solid Dispersion (SD4) And Marketed product (Lessen)



Figure: 4 FT-IR Spectra of Aceclofenac



Figure: 5 FTIR Spectra of ACECLOFENAC& PEG-8000 Mixture

CONCLUSION

The prepared solid dispersions were extended to various characterizations. The solubility and dissolution studies showed there is a possibility of improved solubility of Aceclofenac through solid dispersion with Poly ethylene glycol 8000. The dissolution rate of Aceclofenac from solid dispersions with PEG 8000 improved to more than 51.7 % compared to the pure drug. Further, all the solid dispersions performed better than the corresponding physical mixtures. Also, the saturation solubility of the drug when formulated into solid dispersion with the carrier was higher than that of phase solubility achieved in the presence of the carrier (physical mixture). IR spectra indicated no well-defined interaction between the drug and carrier. A maximum increase in dissolution rate was obtained with Aceclofenac: PEG 8000 solid dispersion with a weight ratio of 1:8. PEG 8000 dispersion by dropping method showed faster dissolution rate when compared with that of physical mixtures of various concentrations and pure drug.

ACKNOWLEDGEMENT

The Author is thankful to M/S Seeko Biotech, Vijayawada for providing gift sample and also thankful to management of St.Paul's college of pharmacy for providing the necessary facility for the study.

ABBREVIATIONS

PEG=PolyEthyleneGlycol, NSAID= Non-steroidal anti-inflammatory Drug, SD=Solid Dispersions, PM=Physical Mixtures, UV=Ultra Violet, IR=Infrared, FDA=Food and Drug administration, DE=Dissolution efficiency, PBS=Phosphate Buffer Solution.

REFERENCES

1. L. F. Huang and W. Q. Tong, Impact of solid state properties on developability assessment of drug candidates, Adv. Drug Del. Rev., 2004, 56, 321–334.
2. M. Pudipeddi, A. T. M. Serajuddin. Trends in solubility of polymorphs. J. Pharm. Sci., 2005, 94, 929–939.
3. D. Q. M. Craig, The mechanisms of drug release from solid dispersions in water- soluble carriers, Int. J. Pharm., 2002, 231, 131–144.
4. W. L. Chiou, S. Riegelman. Pharmaceutical applications of solid dispersions. J. of Pharm. Sci., 1971, 60, 1281–1302.
5. K. Sekiguchi and N. Obi, Studies on absorption of eutectic mixtures – I. A comparison of the behavior of eutectic mixture of sulphathiazole and that of ordinary sulphathiazole in man, Chem. Pharm. Bull., 1961, 9, 866–872.
6. T. Tachibana and A. Nakamura, A method for preparing an aqueous colloidal dispersion of organic material by using water soluble carriers: dispersion of beta-carotene by polyvinylpyrrolidone, Kolloid-Z. Polym., 1965, 203, 130–133.
7. Indian pharmacopoeia, Government of India ministry of Health &Family welfare. The Indian pharmacopoeia commission, Ghaziabad, 2007, vol-2, 681.
8. srinivas mutalik, parambil Anju, Krishna manoj, Achutha nayak usha. Enhancement of dissolution rate and bioavailability of aceclofenac: a chitosan based solvent change approach. Int. journal of pharmaceutics, 2008, 350, 279-290.
9. J. C. Price, Polyethylene Glycol, in Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Washington 1994, 355–361.
10. T. Higuchi and K. Connors, Phase solubility techniques, Adv. Anal. Chem. Instrum., 1965, 4, 117–123.
11. S. Mutalik and S. Prasanna. Once daily sustained release tablets of aceclofenac. Arch Pharm Res, 2007, 30(2), 222-234.

12. Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975; 27(1):48-9.
13. P. Vijayalakshmi and V. Kusum Devi. Development of Extended Zero-Order Release Gliclazide Tablets by Central Composite Design. Drug Development and Industrial Pharmacy, 2008, 34:33–45.
14. M. E. Aulton, Pharmaceutics – The Science of Dosage Form Design, Churchill Livingstone, London 2002, 2nd edition, 8.
15. K. G. Desai and C. Liu, Characteristics of rofecoxib-polyethylene glycol 4000 solid dispersions and tablets based on solid dispersions, Pharma. Dev. Tech., 2005, 10, 467–477.
16. Moreshwar P. Patil, Naresh J. Gaikwad. Preparation and characterization of gliclazide-polyethylene glycol 4000 solid dispersions. Acta Pharm. 2009, 59, 57–65.

***Corresponding author address**:
VENKATEWARA REDDY.BASU
Principal
St. Paul's college of Pharmacy,
Turkayamjal Village,
Hayath Nagar Mandal, R.R. Dt- 501510,
Andhra Pradesh.
Mobile no: +91-9866807609
Email: basu.pharmacist@gmail.com